Patents Examined by Addison D Ault
  • Patent number: 10655148
    Abstract: Compositions and methods are provided employing a helper strain system for promoting genetic alterations in a fungal host cell, e.g., a filamentous fungal host cell.
    Type: Grant
    Filed: December 16, 2015
    Date of Patent: May 19, 2020
    Assignee: DANISCO US INC
    Inventors: Aleksandra Virag, Michael Ward
  • Patent number: 10640816
    Abstract: The present invention relates to, among other things, probes, compositions, methods, and kits for simultaneous, multiplexed detection and quantification of protein and/or nucleic acid expression in a user-defined region of a tissue, user-defined cell, and/or user-defined subcellular structure within a cell.
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: May 5, 2020
    Assignees: NanoString Technologies, Inc., Board of Regents, The University of Texas System
    Inventors: Joseph M. Beechem, Charles Warren, Chris Merritt, Jaemyeong Jung, Dwayne L. Dunaway, Scott Crowder, Kristina Sorg, Gordon B. Mills
  • Patent number: 10590175
    Abstract: The present invention refers to methods for selectively recognizing a base pair in a DNA sequence by a polypeptide, to modified polypeptides which specifically recognize one or more base pairs in a DNA sequence and, to DNA which is modified so that it can be specifically recognized by a polypeptide and to uses of the polypeptide and DNA in specific DNA targeting as well as to methods of modulating expression of target genes in a cell.
    Type: Grant
    Filed: October 4, 2017
    Date of Patent: March 17, 2020
    Inventors: Ulla Bonas, Jens Boch, Sebastian Schornack, Thomas Lahaye
  • Patent number: 10563258
    Abstract: A method for making a skin care composition by identifying connections between cosmetic agents and genes associated with one or more skin aging conditions. The method includes accessing a plurality of instances and at least one skin aging gene expression signature, comparing the at least one skin aging gene expression signature to the plurality of the instances, assigning a connectivity score to each instance based on the comparison and incorporating the cosmetic agent into a skin care composition when the connectivity score of the instance associated with the cosmetic agent has a negative correlation.
    Type: Grant
    Filed: June 25, 2015
    Date of Patent: February 18, 2020
    Assignee: The Procter & Gamble Company
    Inventors: Robert Lloyd Binder, Robert Scott Youngquist, Jun Xu, Kenton Duane Juhlin, Rosemarie Osborne, Scott Michael Hartman
  • Patent number: 10555963
    Abstract: Disclosed is the use of a klotho protein or related compounds (especially KL1 or KL1 analogue) for treatment, and especially treatment of cancer, alone or together with other active pharmaceutical ingredients such as chemotherapeutic agents.
    Type: Grant
    Filed: March 25, 2012
    Date of Patent: February 11, 2020
    Assignee: TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD.
    Inventors: Ido Wolf, Tamar Rubinek, Bella Kaufman, Lilach Abramovitch
  • Patent number: 10557177
    Abstract: A method for characterizing toxicity of toxic pollutants and a method for characterizing comprehensive toxicity of water bodies. The methods include constructing a reporter gene cell line expressing CHOP gene associated with endoplasmic reticulum stress.
    Type: Grant
    Filed: January 11, 2018
    Date of Patent: February 11, 2020
    Assignee: NANJING UNIVERSITY
    Inventors: Bing Wu, Yue Yu, Huimei Chen, Su Liu, Xuxiang Zhang, Hongqiang Ren
  • Patent number: 10550379
    Abstract: Engineered fusion proteins comprising a self-excising degron for controlling protein production are disclosed. In particular, the inventors have constructed fusion proteins comprising a degron connected to a protein of interest through a cleavable linker comprising a hepatitis C virus (HCV) protease site. The degron can be removed from the protein of interest by a czs-encoded HCV protease such that the protein of interest can be produced with minimal structural modification. Clinically available HCV protease inhibitors can be used to block protease cleavage such that the degron is retained after inhibitor addition on subsequently synthesized protein copies. The degron when attached causes rapid degradation of the linked protein. Such fusions of a degron to a protein of interest will be especially useful when control over protein production with minimal structural modification is desired.
    Type: Grant
    Filed: June 28, 2016
    Date of Patent: February 4, 2020
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Michael Z. Lin, Hokyung Chung, Conor Jacobs
  • Patent number: 10539488
    Abstract: It has surprisingly been discovered that it is possible to stabilize biomolecules such as RNA, DNA and proteins in biological samples such as cells, tissues, biopsies and blood using deep eutectic solvents (DES). It has also been discovered that DES mixtures can be used to fix and preserve cell morphology in biological samples such as tissue blocks, cancer biopsies and whole blood. This invention describes methods to stabilize and preserve biomolecules, whole cells, tissues, blood and biological samples using DES mixtures.
    Type: Grant
    Filed: August 14, 2017
    Date of Patent: January 21, 2020
    Assignee: RNASSIST LTD.
    Inventors: Andrew Simon Goldsborough, Malcolm Robert Bates
  • Patent number: 10538799
    Abstract: Disclosed herein are vector systems for expression of polypeptides in eukaryotic cells; and methods of obtaining high-level expression of polypeptides in a eukaryotic cell. Methods and compositions for obtaining stable, long-term expression of recombinant polypeptides are also provided.
    Type: Grant
    Filed: October 11, 2017
    Date of Patent: January 21, 2020
    Assignee: Celltheon Corporation
    Inventor: Amita Goel
  • Patent number: 10512672
    Abstract: This invention provides compositions and methods for preventing inflammatory diseases of the joints, including rheumatoid and osteoarthritis, tendonitis, bursitis, inflammation of the ligament, synovitis, gout, and systemic lupus erythematosus, wherein the methods include injecting into the inflamed joint a therapeutic anti-inflammatory composition comprising a bacterial or viral IL-10 expression construct, wherein the IL-10 expression construct comprises a bacterial or viral backbone and a nucleic acid sequence encoding interleukin-10.
    Type: Grant
    Filed: July 17, 2014
    Date of Patent: December 24, 2019
    Assignees: Xalud Therapeutics, Inc., The Regents of the University of Colorado, a Body Corporate
    Inventors: Raymond A. Chavez, Linda R. Watkins, Robert Landry
  • Patent number: 10508274
    Abstract: Provided herein are, inter alia, methods for linking an mRNA molecule to a polypeptide (e.g., a peptide or a protein) by linking the mRNA molecule to a linking amino acid in the polypeptide, or by linking the mRNA molecule to a linking tRNA to which the polypeptide is attached, via reactions not catalyzed by the ribosome, and methods for making polypeptide libraries. Also provided are mRNA-protein complexes and mRNA-tRNA-protein complexes, libraries containing these complexes, and methods of using these complexes.
    Type: Grant
    Filed: August 19, 2016
    Date of Patent: December 17, 2019
    Assignee: The General Hospital Corporation
    Inventors: Douglas A. Treco, Alonso Ricardo
  • Patent number: 10501777
    Abstract: The present invention relates to, among other things, probes, compositions, methods, and kits for simultaneous, multiplexed detection and quantification of protein expression in a user-defined region of a tissue, user-defined cell, and/or user-defined subcellular structure within a cell.
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: December 10, 2019
    Assignees: NanoString Technologies, Inc., Board of Regents, The University of Texas System
    Inventors: Joseph M. Beechem, Gordon Mills, Charles Warren, Chris Merritt, Jaemyeong Jung, Dwayne L. Dunaway, Scott Crowder
  • Patent number: 10479997
    Abstract: The invention provides novel personalized therapies, kits, transmittable forms of information and methods for use in treating subjects having TMPRSS2:ERG positive prostate cancer, which we show is amenable to therapeutic treatment with a PRMT5 inhibitor. Kits, methods of screening for candidate PRMT5 inhibitors, and associated methods of treatment are also provided.
    Type: Grant
    Filed: December 1, 2015
    Date of Patent: November 19, 2019
    Assignee: NOVARTIS AG
    Inventors: Zineb Mounir, Raymond Pal Pagliarini
  • Patent number: 10457949
    Abstract: Disclosed is a gene multiple insertion cassette set including rDNA NTS fragments and an auxotrophic selection marker having an incomplete promoter is developed, and a safe oral recombinant strain having no antibiotic resistant marker is constructed by multiple insertion of an optimum number of the developed gene multiple insertion cassette sets into chromosomes of a Saccharomyces cerevisiae strain, a vaccine composition including, as an active ingredient, the above strain, a culture product thereof, a cell lysate, or nodavirus capsid protein (NNVcp) isolated and purified therefrom, and a composition for feed addition including, as an active ingredient, the above strain, a culture product thereof, a cell lysate, or squalene or oxidosqualene isolated and purified therefrom.
    Type: Grant
    Filed: December 30, 2014
    Date of Patent: October 29, 2019
    Assignee: CHUNG-ANG UNIVERSITY INDUSTRY-ACADEMY COOPERATION FOUNDATION
    Inventors: Hyun Ah Kang, Hye Yun Moon, Hong Jin Kim
  • Patent number: 10435745
    Abstract: The invention is directed to methods for determining antigen-specific T cells. In some embodiments, methods of the invention may be implemented by the steps of reacting under interaction conditions one or more antigens with T cells in a plurality of subsets of a tissue sample, such as peripheral blood; sorting antigen-interacting T cells from other T cells; separately sequencing for each subset recombined nucleic acid encoding a segment of a TCR chain from a sample of T cells prior to exposure to antigen and from a sample of T cells isolated based on their interaction with antigen, thereby forming a clonotype profile for the former sample and the latter sample for each subset; and identifying as antigen-specific T cells those T cells associated with a clonotype whose frequency increases in the latter sample relative to its frequency in the former sample.
    Type: Grant
    Filed: November 30, 2017
    Date of Patent: October 8, 2019
    Assignee: ADAPTIVE BIOTECHNOLOGIES CORP.
    Inventors: Mark Klinger, Malek Faham
  • Patent number: 10435456
    Abstract: The present invention relates to the field of protein expression. More specifically, the present invention provides compositions and methods for increasing the expression and signaling of proteins on cell surfaces. In particular embodiments, the present invention provides nucleic acids and amino acid sequences useful for improving/increasing protein expression on the cell surface. In several embodiments, the sequences are operably linked to the N-terminal end of the protein of interest. The nucleic acid sequence encoding the sequence tag and the protein can comprise part of an expression vector. The protein can be expressed with the N-terminal sequence tag. In certain embodiments, the sequences of the present invention can be used with one or more chaperone or accessory proteins. In particular embodiments, the one or more chaperone/accessory proteins are encoded by the same vector or separate vectors.
    Type: Grant
    Filed: January 29, 2015
    Date of Patent: October 8, 2019
    Assignee: The Johns Hopkins University
    Inventors: Jennifer Pluznick, Blythe Shepard, Niranjana Natarajan
  • Patent number: 10435741
    Abstract: Compositions, devices, systems and methods for increasing the signal to noise ratio (SNR) and/or enhancing photoprotection in an illuminated analytical reaction by addition of one or more signal detection assay (SDA)-enhancing agents to the reaction mixture.
    Type: Grant
    Filed: November 18, 2016
    Date of Patent: October 8, 2019
    Assignee: Pacific Biosciences of California, Inc.
    Inventors: Stephen Yue, Andrei Fedorov, Gene Shen, Sophia Wu
  • Patent number: 10415055
    Abstract: Expression-enhancing nucleotide sequences for expression in eukaryotic systems are provided that allow for enhanced and stable expression of recombinant proteins in eukaryotic cells. Enhanced expression and stability regions (EESYRs) are provided for expression of a gene of interest in a eukaryotic cell. Chromosomal loci, sequences, and vectors are provided for enhanced and stable expression of genes in eukaryotic cells.
    Type: Grant
    Filed: March 9, 2018
    Date of Patent: September 17, 2019
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Gang Chen, Robert Babb, James P. Fandl
  • Patent number: 10406236
    Abstract: The present invention provides soluble single wall nanotube (SWNT) constructs functionalized with a plurality of a targeting moiety and a plurality of one or more payload molecules attached thereto. The targeting moiety and the payload molecules may be attached to the soluble SWNT via a DNA or other oligomer platform attached to the SWNT. These soluble SWNT constructs may comprise a radionuclide or contrast agent and as such are effective as diagnostic and therapeutic agents. Methods provided herein are to diagnosing or locating a cancer, treating a cancer, eliciting an immune response against a cancer or delivering an anticancer drug in situ via an enzymatic nanofactory using the soluble SWNT constructs.
    Type: Grant
    Filed: April 24, 2017
    Date of Patent: September 10, 2019
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: David A. Scheinberg, Michael R. McDevitt, Christophe Antczak, Debjit Chattopadhyay, Rena May, Jon Njardarson, Mark Reid Phillips
  • Patent number: 10393633
    Abstract: It has surprisingly been discovered that it is possible to stabilize biomolecules such as RNA, DNA and proteins in biological samples such as cells, tissues, biopsies and blood using deep eutectic solvents (DES). It has also been discovered that DES mixtures can be used to fix and preserve cell morphology in biological samples such as tissue blocks, cancer biopsies and whole blood. This invention describes methods to stabilize and preserve biomolecules, whole cells, tissues, blood and biological samples using DES mixtures.
    Type: Grant
    Filed: May 30, 2017
    Date of Patent: August 27, 2019
    Assignee: RNASSIST LTD.
    Inventors: Andrew Simon Goldsborough, Malcolm Robert Bates